987. Repeated Exposure to an Adjuvanted Quadrivalent Subunit Influenza Virus Vaccine (aQIV): A Randomized, Observer Blind, Multicenter Study

Ítems similars

• Influenza vaccination in children primed with MF59(®)-adjuvanted or non-adjuvanted seasonal influenza vaccine
  per: Vesikari, Timo, et al.
  Publicat: (2015)
• Immunogenicity and safety of a quadrivalent meningococcal tetanus toxoid-conjugate vaccine (MenACYW-TT) in healthy toddlers: a Phase II randomized study
  per: Vesikari, Timo, et al.
  Publicat: (2020)
• Immunogenicity and Safety of an MF59-adjuvanted Quadrivalent Seasonal Influenza Vaccine in Young Children at High Risk of Influenza-associated Complications: A Phase III, Randomized, Observer-blind, Multicenter Clinical Trial
  per: Esposito, Susanna, et al.
  Publicat: (2020)
• Antibody persistence up to 5 years after vaccination of toddlers and children between 12 months and 10 years of age with a quadrivalent meningococcal ACWY-tetanus toxoid conjugate vaccine
  per: Vesikari, Timo, et al.
  Publicat: (2015)
• Cumulative clinical experience with MF59-adjuvanted trivalent seasonal influenza vaccine in young children
  per: Sanjay S. Patel, et al.
  Publicat: (2019-08-01)